Holen Sie sich die Stockscreener-App
280.96
3.35%
-9.74
Handel nachbörslich:
280.96
Schlusskurs vom Vortag:
$290.70
Offen:
$290.05
24-Stunden-Volumen:
1.05M
Relative Volume:
1.46
Marktkapitalisierung:
$36.37B
Einnahmen:
$2.25B
Nettoeinkommen (Verlust:
$-278.16M
KGV:
-129.47
EPS:
-2.17
Netto-Cashflow:
$-42.59M
1W Leistung:
+15.01%
1M Leistung:
+14.58%
6M Leistung:
+3.02%
1J Leistung:
+84.76%
1-Tages-Spanne:
$280.33
$292.62
1-Wochen-Bereich:
$243.44
$300.90
52-Wochen-Spanne:
$141.97
$304.39
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Firmenname
Alnylam Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 551-8200
Adresse
675 WEST KENDALL STREET, CAMBRIDGE, MA
Vergleichen Sie ALNY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
280.96 | 36.37B | 2.25B | -278.16M | -42.59M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
509.04 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.14 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
605.52 | 36.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ONC
Beigene Ltd Adr
|
250.47 | 27.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-12 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-16 | Hochstufung | Goldman | Neutral → Buy |
| 2024-02-16 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-10-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-05-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-06-07 | Eingeleitet | William Blair | Outperform |
| 2022-04-25 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Eingeleitet | Citigroup | Buy |
| 2022-02-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-01-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Hochstufung | Goldman | Neutral → Buy |
| 2021-11-22 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-08-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-02-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-02-12 | Bestätigt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Fortgesetzt | Berenberg | Hold |
| 2020-09-08 | Eingeleitet | Citigroup | Buy |
| 2020-08-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-03-19 | Eingeleitet | Berenberg | Buy |
| 2019-12-19 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Bestätigt | Stifel | Buy |
| 2018-08-07 | Hochstufung | Stifel | Hold → Buy |
| 2018-05-04 | Bestätigt | Stifel | Hold |
| 2018-03-28 | Eingeleitet | Evercore ISI | In-line |
Alle ansehen
Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten
Alnylam Pharmaceuticals director David Pyott sells $2.2 million in stock - Investing.com India
Alnylam Pharmaceuticals CMO Pushkal Garg sells $2.86 million in stock By Investing.com - Investing.com UK
Alnylam Pharmaceuticals’ SWOT analysis: stock poised for growth in expanding ATTR-CM market - Investing.com
FDA approves new drug to treat protein buildup in the heart - UPI News
Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock - Benzinga
FDA OKs Amvuttra To Treat Heart Conditions - The Daily Courier
Alnylam Pharmaceuticals Stock (ALNY): Innovative Treatment for ATTR Amyloidosis - Value the Markets
Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains? - Yahoo Finance
RBC Capital holds $330 target on Alnylam stock post-Amvuttra approval - Investing.com UK
Carnival To Rally Around 48%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
JPMorgan Upgrades Alnylam Pharmaceuticals to Overweight From Neutral, Adjusts Price Target to $328 From $280 - Marketscreener.com
Alnylam Pharmaceuticals, Beacon Roofing, Liberty Energy - TradingView
JPMorgan raises Alnylam stock rating, lifts target to $328 - Investing.com
Alnylam Heart Drug Approval Sets Up Challenge With Pfizer - MSN
Alnylam Pharmaceuticals (NasdaqGS:ALNY) Sees 17% Weekly Gain As Vutrisiran Faces FDA Decision - Simply Wall St
Robinhood, Roku And Shopify Are Among Top 10 Large-Cap Gainers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio? - Benzinga
Alnylam Wins Expanded Heart Drug Approval, Challenging Pfizer - MSN
Alnylam price target raised to $338 from $300 at Scotiabank - Yahoo Finance
Alnylam Pharmaceuticals’ SWOT analysis: RNAi leader’s stock poised for growth in ATTR-CM market - Investing.com
Teenager dies after receiving Sarepta therapy; Immunovant gets Phase 3 win, but shifts focus; Alnylam’s big moment; and more - Endpoints News
Alnylam Stock Jumps After the FDA Approves Its Heart Drug - The Wall Street Journal
Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster (NASDAQ:ALNY) - Seeking Alpha
U.S. Markets Moved Upward Friday; Alnylam Pharmaceuticals Climbed Highest - Barron's
Alnylam: US Approval of Amvuttra in ATTR-CM Significantly Expands Addressable Patient Population - Morningstar
Alnylam hopes its broad ATTR-CM label can give Amvuttra an edge in heart disease - Endpoints News
Buy, Sell, Or Hold Alnylam Stock At $280? - Forbes
Check Out What Whales Are Doing With ALNY - Benzinga
Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drug - Yahoo Finance
Alnylam Pharma Stock (ALNY) Rockets on FDA Drug Approval - TipRanks
Alnylam Drug Approval Brings Cardiomyopathy Competition to Pfizer, BridgeBio Pharma - MedCity News
Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy - Yahoo Finance
Alnylam jumps as expanded US approval for heart disease drug fuels growth prospects - MSN
Alnylam prices heart drug at premium to rivals - BioPharma Dive
Alnylam Expanded Heart Drug Approval Sets Up Pfizer Challenge - MSN
Alnylam's Amvuttra Gains Expanded US Approval for Heart ConditionNews and Statistics - IndexBox, Inc.
BofA Securities Raises Price Target on Alnylam Pharmaceuticals to $325 From $302, Keeps Buy Rating - Marketscreener.com
Alnylam Pharmaceuticals Shares Rise After Receipt of US FDA Approval for ATTR-CM Drug - Marketscreener.com
Alnylam (ALNY) Heart Drug Amvuttra Wins Expanded Approval, Challenging Pfizer - Bloomberg
Alnylam's Amvuttra Secures FDA Approval For Expanded Use For Rare Heart Disease, Stock Jumps - Benzinga
Sector Update: Health Care -March 21, 2025 at 09:20 am EDT - Marketscreener.com
Sector Update: Health Care - TradingView
RBC Adjusts Price Target on Alnylam Pharmaceuticals to $330 From $310, Maintains Outperform Rating - Marketscreener.com
Alnylam scores a first with FDA nod for Amvuttra in ATTR-CM - The Pharma Letter
Alnylam shares rise on expanded heart drug approval - TradingView
Alnylam stock rises after FDA nod for AMVUTTRA By Investing.com - Investing.com Canada
Alnylam joins three-way contest in ATTR cardiomyopathy - pharmaphorum
Alnylam’s SWOT analysis: biotechnology stock poised for growth amid ATTR-CM market expansion - Investing.com
Alnylam Pharmaceuticals Recieives US FDA Approval for ATTR-CM Drug -March 21, 2025 at 03:59 am EDT - Marketscreener.com
Alnylam drug gets long-awaited FDA approval in deadly heart disease - BioPharma Dive
FDA Approves Alnylam’s Vutrisiran for the Treatment of ATTR Amyloidosis With Cardiomyopathy - CGTLive™
Alnylam nabs key additional indication for Amvuttra - MSN
Finanzdaten der Alnylam Pharmaceuticals Inc-Aktie (ALNY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.40%
0.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):